{"transactions":[{"id":944238,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944237,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":22.81,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944236,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":12.64,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944235,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2125,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":23.4,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944234,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":10.6,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944233,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":38.4,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944232,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":875,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":79.4,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":875},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944231,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":32,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944230,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":106,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944229,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":550,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":138,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":550},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944228,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"shares","element":"transactionShares","label":"F5","text":"The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option."}],"balance_after":0,"derivative":{"exercise_price":204.4,"expiration_date":"2026-06-21","underlying":"Common Stock","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":944227,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-07T20:17:13.000Z","date":"2026-01-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150,"price":221.5,"value":33225.0,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the \"Issuer\"), Merck Sharp & Dohme LLC (\"Merck\") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck (\"Purchaser\"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a \"Common Share\") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a \"Series A Share\"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the \"Merger\"). [continues to Footnote 2]"},{"field":"kind","element":"transactionCoding","label":"F2","text":"[continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the \"Common Share Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the \"Series A Merger Consideration\"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes."},{"field":"shares","element":"transactionShares","label":"F4","text":"The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001239650-26-000002","document":"wk-form4_1767835029.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000123965026000002/wk-form4_1767835029.xml","form_type":"4"}},{"id":1106078,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-18T17:03:43.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders."}],"balance_after":11100,"derivative":{"exercise_price":21.31,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":11100},"source":{"system":"sec-edgar","filing":"0001610618-25-000063","document":"wk-form4_1750280616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000161061825000063/wk-form4_1750280616.xml","form_type":"4"}},{"id":1325216,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-19T18:20:55.000Z","date":"2024-12-17","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of December 17, 2024."}],"balance_after":20500,"derivative":{"exercise_price":22.81,"expiration_date":"2034-12-16","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001610618-24-000156","document":"wk-form4_1734650448.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000161061824000156/wk-form4_1734650448.xml","form_type":"4"}},{"id":1451130,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-19T16:56:42.000Z","date":"2024-07-18","kind":"grant","planned":false,"acquired":true,"shares":2125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders."}],"balance_after":2125,"derivative":{"exercise_price":12.64,"expiration_date":"2034-07-17","underlying":"Common Stock","underlying_shares":2125},"source":{"system":"sec-edgar","filing":"0001610618-24-000108","document":"wk-form4_1721422595.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000161061824000108/wk-form4_1721422595.xml","form_type":"4"}},{"id":1501884,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-24T20:17:52.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable as of the date of the grant."}],"balance_after":67000,"derivative":{"exercise_price":3.28,"exercise_date":"2024-05-23","expiration_date":"2034-05-23","underlying":"Common Shares","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001447028-24-000059","document":"wk-form4_1716581859.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702824000059/wk-form4_1716581859.xml","form_type":"4"}},{"id":1845038,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T17:19:51.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":42500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2024 annual meeting of stockholders."}],"balance_after":42500,"derivative":{"exercise_price":1.17,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":42500},"source":{"system":"sec-edgar","filing":"0001610618-23-000065","document":"wf-form4_168755517549260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000161061823000065/wf-form4_168755517549260.xml","form_type":"4"}},{"id":1876389,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-26T20:22:45.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 24, 2023, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable as of the date of the grant."}],"balance_after":55000,"derivative":{"exercise_price":2.56,"exercise_date":"2023-05-24","expiration_date":"2033-05-24","underlying":"Common Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001447028-23-000046","document":"wk-form4_1685132533.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702823000046/wk-form4_1685132533.xml","form_type":"4"}},{"id":2194349,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-04T18:24:25.000Z","date":"2022-08-02","kind":"sale","acquired":false,"shares":11341,"price":0.1901,"value":2155.9241,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":10384,"source":{"system":"sec-edgar","filing":"0001104659-22-086282","document":"tm2222534-13_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465922086282/tm2222534-13_4seq1.xml","form_type":"4"}},{"id":2221901,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T17:33:17.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2023 annual meeting of stockholders."}],"balance_after":28000,"derivative":{"exercise_price":0.53,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001610618-22-000058","document":"wf-form4_165610638397871.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000161061822000058/wf-form4_165610638397871.xml","form_type":"4"}},{"id":2255141,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-26T20:17:55.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 25, 2022, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable as of the date of the grant."}],"balance_after":41000,"derivative":{"exercise_price":2.25,"exercise_date":"2022-05-25","expiration_date":"2032-05-25","underlying":"Common Shares","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001447028-22-000037","document":"wf-form4_165359625754672.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702822000037/wf-form4_165359625754672.xml","form_type":"4"}},{"id":2614560,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-08-04T21:07:10.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":1125,"price":1.2,"value":1350.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.205, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":21725,"source":{"system":"sec-edgar","filing":"0001104659-21-100290","document":"tm2123911-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465921100290/tm2123911-7_4seq1.xml","form_type":"4"}},{"id":2621101,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-07-30T20:23:14.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option was granted on July 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":1.08,"expiration_date":"2031-07-27","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-21-098429","document":"tm2123737d8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465921098429/tm2123737d8_4seq1.xml","form_type":"4"}},{"id":2621100,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-30T20:23:14.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020."}],"balance_after":22850,"source":{"system":"sec-edgar","filing":"0001104659-21-098429","document":"tm2123737d8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465921098429/tm2123737d8_4seq1.xml","form_type":"4"}},{"id":2655712,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T17:55:06.000Z","date":"2021-06-23","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2022 annual meeting of stockholders."}],"balance_after":17500,"derivative":{"exercise_price":1.92,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001610618-21-000052","document":"wf-form4_162457168309920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000161061821000052/wf-form4_162457168309920.xml","form_type":"4"}},{"id":2679211,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-06-07T20:25:44.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are fully vested and exercisable as of the date of the grant."}],"balance_after":22000,"derivative":{"exercise_price":2.95,"exercise_date":"2021-06-03","expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001447028-21-000044","document":"wf-form4_162309752909256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702821000044/wf-form4_162309752909256.xml","form_type":"4"}},{"id":3072366,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-07-31T16:54:20.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The option was granted on July 29, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the option will vest on July 31, 2021, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":0.79,"expiration_date":"2030-07-28","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-20-089139","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465920089139/a4.xml","form_type":"4"}},{"id":3072365,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-07-31T16:54:20.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."}],"balance_after":53500,"source":{"system":"sec-edgar","filing":"0001104659-20-089139","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465920089139/a4.xml","form_type":"4"}},{"id":3099652,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T18:48:42.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2021 annual meeting of stockholders."}],"balance_after":17500,"derivative":{"exercise_price":3.97,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001140361-20-014775","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000114036120014775/form4.xml","form_type":"4"}},{"id":3128968,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2020-06-01T20:56:18.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 28, 2020, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options are fully vested and exercisable as of the date of the grant."}],"balance_after":22000,"derivative":{"exercise_price":2.16,"exercise_date":"2020-05-28","expiration_date":"2030-05-28","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001447028-20-000063","document":"wf-form4_159104495703408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702820000063/wf-form4_159104495703408.xml","form_type":"4"}},{"id":3433125,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-08-20T20:17:03.000Z","date":"2019-08-17","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on August 16, 2019, the trading day immediately preceding the date of the grant."}],"balance_after":22000,"derivative":{"exercise_price":1.5,"exercise_date":"2019-08-17","expiration_date":"2029-08-17","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001447028-19-000054","document":"wf-form4_156633220629149.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000144702819000054/wf-form4_156633220629149.xml","form_type":"4"}},{"id":3450751,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-08-01T16:20:34.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $2.38 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"expiration_date":"2029-07-31","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-19-043347","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465919043347/a4.xml","form_type":"4"}},{"id":3476806,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-27T17:00:58.000Z","date":"2019-06-17","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2020 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2020 annual meeting of stockholders."}],"balance_after":11000,"derivative":{"exercise_price":1.6,"expiration_date":"2029-06-16","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-19-039296","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000120919119039296/doc4.xml","form_type":"4"}},{"id":3854870,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-08-02T17:51:52.000Z","date":"2018-08-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $2.53 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option award was granted on August 1, 2018. The option award will vest in full on August 1, 2019."}],"balance_after":15000,"derivative":{"expiration_date":"2028-08-01","underlying":"Ordinary Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-18-049250","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465918049250/a4.xml","form_type":"4"}},{"id":3854869,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-08-02T17:51:52.000Z","date":"2018-07-31","kind":"purchase","acquired":true,"shares":36000,"price":2.75,"value":99000.0,"ownership":{"direct":true},"balance_after":36000,"source":{"system":"sec-edgar","filing":"0001104659-18-049250","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465918049250/a4.xml","form_type":"4"}},{"id":3884990,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-06-22T15:21:05.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":6.75,"exercise_date":"2018-06-19","expiration_date":"2028-06-19","underlying":"Common Shares","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001140361-18-029561","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000114036118029561/doc1.xml","form_type":"4"}},{"id":3892263,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-15T16:27:52.000Z","date":"2018-06-13","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2019 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2019 annual meeting of stockholders."}],"balance_after":11000,"derivative":{"exercise_price":5.3,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-18-038056","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000120919118038056/doc4.xml","form_type":"4"}},{"id":3945394,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-05-04T16:06:27.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $4.91 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019."}],"balance_after":29000,"derivative":{"expiration_date":"2028-05-02","underlying":"Ordinary Shares","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001104659-18-030634","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465918030634/a4.xml","form_type":"4"}},{"id":4205504,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-09-19T21:32:21.000Z","date":"2017-09-15","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $6.86 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018."}],"balance_after":10100,"derivative":{"expiration_date":"2027-09-15","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-057955","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465917057955/a4.xml","form_type":"4"}},{"id":4271584,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:55:06.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017."}],"balance_after":10100,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-041902","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465917041902/a4.xml","form_type":"4"}},{"id":4271583,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:55:06.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":20200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016."}],"balance_after":20200,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":20200},"source":{"system":"sec-edgar","filing":"0001104659-17-041902","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000110465917041902/a4.xml","form_type":"4"}},{"id":4273378,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-23T16:59:03.000Z","date":"2017-06-22","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2018 annual meeting of stockholders."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2018 annual meeting of stockholders."}],"balance_after":11000,"derivative":{"exercise_price":6.9,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-17-041699","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1239650/000120919117041699/doc4.xml","form_type":"4"}},{"id":4274534,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option Grant (Right to Buy)","published_at":"2017-06-22T20:58:22.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":22000,"derivative":{"exercise_price":3.55,"exercise_date":"2017-06-21","expiration_date":"2027-06-21","underlying":"Common Shares","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001140361-17-025877","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000114036117025877/doc1.xml","form_type":"4"}},{"id":4371483,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":69834,"kind":"person","name":"BURGESS DANIEL D","position":1,"cik":"0001239650","reported_name":"BURGESS DANIEL D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2017-03-27T20:26:10.000Z","date":"2017-03-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 1/3 on March 23, 2018; 1/3 on March 23, 2019; 1/3 on March 23, 2020."}],"balance_after":50000,"derivative":{"exercise_price":3.15,"expiration_date":"2027-03-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-17-013440","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000114036117013440/doc1.xml","form_type":"4"}}]}